Trends in anti-osteoporosis pharmacotherapy and pharmacological initiation for secondary fracture prevention in Japan, 2017-2023 - PubMed
3 hours ago
- #Osteoporosis Treatment
- #Pharmacoepidemiology
- #Fracture Prevention
- Study examined trends in anti-osteoporosis pharmacotherapy in Japan from 2017 to 2023.
- Assessed impact of April 2022 management fee for post-hip fracture care on secondary fracture prevention after hip and vertebral fractures.
- Found increased initiation of anti-osteoporosis medication within 3 months after hip fracture post-2022, reaching 29.5% in 2023.
- Slight increase in medication initiation after vertebral fracture, reaching 35.7% in 2023.
- Shift in agent-specific initiation: increased oral bisphosphonates and decreased teriparatide after hip fracture; decreased other medications after both fractures.
- Introduction of romosozumab led to increased initiation after both fractures.
- Calls for further research to assess sustainability and implications of these trends in post-fracture osteoporosis care.